Targetted CML treatments

Heasman, Sally-Anne, Small, Matthew and MacEwan, David (2011) Targetted CML treatments. British Oncology Pharmacy Association Bulletin, 3. pp. 11-15.

Full text not available from this repository.

Abstract

The introduction of the tyrosine kinase inhibitor (TKI), imatinib, has had a significant impact in improving the long term survival prospects of patients with chronic myeloid leukaemia (CML). However, many patients develop resistance to imatinib, which has prompted the development of more potent TKIs and other new agents with different mechanisms of action. This article examines how TKIs work in CML, describes mutations that may develop to confer resistance and discusses

Item Type:	Article
Faculty \ School:	Faculty of Science > School of Environmental Sciences Faculty of Science Faculty of Science > School of Pharmacy
Depositing User:	Rachel Smith
Date Deposited:	11 Aug 2011 10:37
Last Modified:	30 Sep 2021 01:25
URI:	https://ueaeprints.uea.ac.uk/id/eprint/34462
DOI:

Actions (login required)

View Item